An American company called Regeneron has developed a drug that can help treat the symptoms of the epidemic Reuters.
A statement issued by Roche, the company’s manufacturing partner, wrote that in a phase III clinical trial, the effect of a cocktail containing antibodies was studied among people who lived in a household with coronavirus infection.
And they claimed that people had an 81% lower risk of developing symptoms.
In addition, those who experienced symptoms of the infection overcome them much earlier. The statement said they had symptoms on average one week, while those who received a placebo instead of a cocktail had an average of three weeks.
The cocktail, which works under the product name REGEN-COV, contains two monoclonal antibodies, casirivimab and imdevimab. The product has already been approved for emergency use by the U.S. Medicines Agency and the European Medicines Agency (EMA) has also issued a recommendation for its use.
In both cases, attention was drawn to the fact that the product is not recommended for treating those who have been ventilated and is primarily suitable for preventing more serious diseases.
Recent studies have also revealed that the cocktail does not work against some variants of the viruses.
According to Regeneron, Donald Trump was also treated with the product in October 2020, at the specific request of the US President’s doctors.